Table 1.

Characteristics of the included studies

Study	Year	Time frame	Level of evidencea	Quality scoreb	Country	Age (years)c	Total pts. (n)	Male	Female	Median follow-up (months)	Outcome
Martin, E. et al.	2020	1989–2017	3b	7	Netherlands	49	784	421	363	NA	OS
Yan, P. H. et al.	2019	1973–2014	3b	6	Chinad	45	689	340	349	NA	OS
van Noesel, M. M. et al.	2019	2005–2016	3b	7	Five European countries	13.7	51	25	26	64.6	OS/EFS/LR
Shurell-Linehan, E. et al.	2019	1974–2012	4	7	USA	32.5	38	30	8	12.5	DSS/DFS
Mowery, A. et al.	2019	2004–2015	3b	6	USAe	47	2858	1554	1304	30.5	OS
Miao, R. Y. et al.	2019	1960–2016	3b	7	USA	41	280	138	142	43.1	OS/PFS/LR
Bergamaschi, L. et al.	2018	1979–2004	3b	7	Italy	< 21	73	37	36	NA	OS/LR
Yuan, Z. N. et al.	2017	1999–2016	3b	6	China	40	159	81	78	31	OS/TFS/LR
Watson, K. L. et al.	2017	1990–2014	3b	7	USA	37	289	155	134	25.56/ 26.16/ 20.88 f	DSS /LR
Vasconcelos, R. A. T. et al.	2017	1990–2010	4	7	Brazil	43.5	92	41	51	24.8	OS/LR
Hwang, I. K. et al.	2017	1988–2015	3b	7	Korea	40.4	95	50	45	NA	OS
Valentin, T. et al.	2016	1990–2013	3b	7	France	42	340	190	150	87.6	OS/DFS
Wang, T. et al.	2015	2001–2012	4	7	China	50	43	25	18	24	OS/LR
Ma, C. et al.	2014	1996–2012	4	6	China	41	43	25	18	NA	OS/LR
Goertz, O. et al.	2014	1991-2004	4	5	Germany	54	65	32	33	36	OS /LR
Fan, Q. et al.	2014	NA	3b	6	China	40	146	79	67	NA	OS/TFS
LaFemina, J. et al.	2013	1982–2011	3b	6	USA	38	105	71	34	31.2	DSS/LR
Kamran, S. C. et al.	2013	1999–2011	3b	7	USA	43.2	84	47	37	19	LR
Stucky, C. C. et al.	2012	1985–2010	3b	7	USA	44	175	85	90	74	DSS/LR
Rekhi, B. et al.	2010	2002–2006	4	5	India	39	63	46	17	NA	LR
Longhi, A. et al.	2010	1969–2008	3b	7	Italy	39	62	39	23	54	OS/DFS/LR
Porter, D. E. et al.	2009	1979–2002	3b	7	UK	26/53g	123	NA	NA	6–252h	OS/LR
Keizman, D. et al.	2009	1994–2006	4	6	Israel	41	46	30	16	47	LR
Okada, K. et al.	2007	1994–2002	3b	7	Japan	45	56	22	34	41	OS/LR
Anghileri, M. et al.	2006	1976–2003	3b	7	Italy	37	205	108	97	NA	CSS/LR
Carli, M. et al.	2005	1975–1998	3b	6	Germany and Italy	11	167	83	84	87.6	OS/PFS
Meis, J. M. et al.	1992	1965–1985	4	7	USA	10	47	42	36	22	LR
Nambisan, R. N. et al.	1984	1971–1981	4	5	USA	35	31	16	15	NA	LR

NA not available, OS overall survival, CSS cause-specific survival, DSS disease-specific survival, EFS event-free survival, DFS disease-free survival, TFS tumor-free survival, PFS progression-free survival, LR local recurrence

^aLevel of evidence: according to the criteria of the Centre for Evidence-Based Medicine

^bQuality score: the score of the study using the Newcastle–Ottawa Scale

^cAge is represented by the median, or the average, or the range age of the study population

^dYan, P. H. et al. (2019) used the data of SEER database

^eMowery, A. et al. (2019) used the data of NCDB

^fThe median follow-up interval was 25.56 for sporadic, 26.16 for NF1-associated, and 20.88 for RT-associated MPNST

^gThe median age was 26 for NF1 MPNST, 53 for sporadic MPNST

^hThe follow-up time ranged from 6 to 252 months